Filed by Flex Pharma, Inc.
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule
under the Securities Exchange Act of 1934
Subject Company: Salarius Pharmaceuticals, LLC
SEC File No.:
Flex Pharma, Inc. intends to issue the following press release.
Flex Pharma Announces Approval of all Merger-Related Proposals at Special Meeting
BOSTON(BUSINESS WIRE)July 12, 2019 Flex Pharma, Inc. (Nasdaq: FLKS) today announced that its stockholders approved all proposals relating to
its planned merger with Salarius Pharmaceuticals, LLC at Flex Pharmas special meeting of stockholders. Flex Pharma will file a Form
to disclose detailed voting results for each proposal. Flex Pharma
expects to complete the merger within the next week or two.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, LLC is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that
need them the most. The companys lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Pediatric Rare Disease Designation by the U.S. Food and Drug
Administration. Salarius believes that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other
LSD1-targeted therapies. Salarius is also developing Seclidemstat for a number of cancers with high unmet need and expects to commence additional clinical studies in 2019 targeting advanced solid tumors, including prostate, breast and ovarian
cancers. For more information, please visit salariuspharma.com.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that was founded in 2014 by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate) and
Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology.
Additional Information and Where to Find It
communication may be deemed to be solicitation material in respect of the proposed transaction. In connection with the proposed transaction, Flex Pharma filed with the Securities and Exchange Commission (SEC) a registration statement on Form
containing a proxy statement / prospectus / information statement, which took effect on April 29, 2019. On April 30, 2019, Flex Pharma
filed a definitive proxy statement / prospectus / information statement with the SEC. On or around May 3, 2019, Flex Pharma began mailing the definitive proxy statement / prospectus / information statement to Flex Pharma stockholders of record
as of the close of business on April 17, 2019. FLEX PHARMA URGES INVESTORS AND EQUITYHOLDERS OF FLEX PHARMA AND SALARIUS TO READ THE DEFINITIVE PROXY STATEMENT / PROSPECTUS / INFORMATION